Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Mar 31, 2026

Bloom Energy (BE): Navigating AI Power Demands with a $20 Billion Backlog

Key Takeaways

  • Bloom Energy's $20 billion backlog, including $6 billion in product orders up 2.5x year-over-year, signals robust demand from AI data centers and hyperscalers.
  • Strategic partnerships like the $5 billion Brookfield deal and $2.65 billion AEP agreement position BE as a leader in onsite power for AI infrastructure.
  • 2026 revenue guidance of $3.1B-$3.3B, with non-GAAP gross margins around 32%, outpaces consensus estimates and highlights operating leverage.
  • Analyst consensus leans "Hold" with an average price target near $140-$150, reflecting mixed views amid high valuations but strong growth prospects.
  • Grid constraints and AI power needs create tailwinds, amplified by 30% Investment Tax Credit (ITC) for fuel cells starting 2026.
  • Execution risks include manufacturing scale-up to 2 GW capacity and competition from batteries or turbines, potentially impacting margins.

Bloom Energy's Strategic Positioning in the SOFC Market

In my view, Bloom Energy maintains a strong position in the solid oxide fuel cell (SOFC) market, especially for onsite, distributed power generation. Its proprietary Energy Servers deliver up to 60% electrical efficiency on hydrogen, which outperforms many competitors, and provide fuel flexibility across natural gas, biogas, and hydrogen. This capability supports low-emission, resilient power for critical applications such as data centers and industrial sites.

The company leads U.S. commercial and industrial (C&I) SOFC deployments, with over 1.4 GW installed globally and 80% market share in key regions like South Korea. Key advantages include rapid deployment—taking weeks compared to years for grid upgrades—and modular scalability from hundreds of kW to GW-scale. Plans to expand manufacturing to 2 GW annual capacity by the end of 2026 will help meet hyperscaler demand. I also checked this using Tickeron’s AI Screener to compare BE against others in the industry.

Although it faces competition from players like FuelCell Energy or gas turbines, Bloom's $14 billion service backlog provides recurring revenue for medium-term stability. International growth through partnerships aims at data centers in emerging markets.

Key Catalysts on the Horizon

The upcoming Q1 2026 earnings on April 27 will be important for confirming progress toward the $3.1B-$3.3B full-year revenue guidance, with consensus EPS at $0.12 and revenue at $570M. Successfully doubling capacity to 2 GW remains essential for converting the backlog.

Partnerships such as the $5B Brookfield deal for AI data centers and AEP's 1 GW order demonstrate wins with hyperscalers, which could lead to more as grid constraints intensify. Deployments with Oracle and CoreWeave point to broader adoption.

The January 2026 ITC restoration, providing 30% credits on fuel cells, will reduce customer costs and drive orders. Following the Q4 2025 beat, analysts like JP Morgan raised targets to $166 (Overweight) and Jefferies to $92 (Underperform), indicating optimism balanced by valuation concerns. The consensus "Hold" rating with targets between $131-$152 suggests modest upside, though successful backlog execution could prompt upgrades.

Industry Tailwinds and Macro Factors

From what I see, Bloom benefits from the AI-driven power surge, as data centers plan for 1 GW+ scales by 2030. Grid delays of 5-7 years make onsite solutions attractive, especially with the U.S. DOE projecting a 100 GW deficit.

Lower interest rates should facilitate capex for deployments, while Inflation Reduction Act (IRA) incentives like Section 48E ITC improve economics to match gas turbines. Hydrogen transitions support net-zero goals, with natural gas serving near-term needs.

Geopolitical tensions underscore energy security, favoring U.S.-based manufacturing. The solid oxide fuel cell market is projected to grow at a 24% CAGR to $9.6B by 2030, fueled by clean energy mandates and data center localization.

2026 Outlook and Themes to Monitor

Bloom's 2026 guidance calls for $3.1B-$3.3B in revenue (over 50% growth), 32% non-GAAP gross margins, and $425M-$475M in operating income, setting a solid foundation amid the AI power expansion. Converting the backlog and ramping to 2 GW capacity will be critical for execution.

Longer-term, expansion into hyperscale data centers and utilities holds multi-GW potential, complemented by SOEC electrolyzers for green hydrogen. Scale-driven cost reductions and recycling (99.5% materials reusable) should expand margins into the mid-20s% range.

Threats from batteries or nuclear remain, but fuel flexibility and quick deployment set Bloom apart. Regulatory support from IRA credits and state incentives strengthens its position. Consensus forecasts EPS at $0.96 for 2026, climbing to $2.50 in 2027, which will influence sentiment if achieved. Capital allocation focuses on Fremont expansion and R&D for 800V DC servers, balancing growth with cash flow approaching $200M.

Trend Prediction Engine

I rely on Tickeron’s Trend Prediction Engine in my analysis—it's an AI-powered tool that forecasts whether a stock like BE, ETFs, or other assets might trend bullish, bearish, or sideways over the next week or month. Drawing on machine learning, it examines historical patterns, technical indicators, and market data to highlight trends, potential breakouts or reversals, and predictions across various instruments. Features like timeframe-based searches, historical signal performance, and customizable alerts help me stay ahead. Whether you're new to trading or seasoned, it delivers actionable insights. I've found it invaluable for refining my market outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: BE

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BE in upward trend: 10-day moving average moved above 50-day moving average on September 09, 2026

The 10-day moving average for BE crossed bullishly above the 50-day moving average on September 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on BE as a result. In 61 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for BE just turned positive on October 02, 2026. Looking at past instances where BE's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.

BE moved above its 50-day moving average on September 03, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +4.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where BE advanced for three days, in 266 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

The Aroon Indicator entered an Uptrend today. In 243 of 263 cases where BE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for BE moved out of overbought territory on September 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 36 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 60 cases where BE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

BE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. BE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BE's P/B Ratio (48.077) is very high in comparison to the industry average of (7.529). BE's P/E Ratio (341.390) is considerably higher than the industry average of (54.807). Projected Growth (PEG Ratio) (0.594) is also within normal values, averaging (2.900). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (24.876) is also within normal values, averaging (8.080).

Notable companies

The most notable companies in this group are Bloom Energy Corp (NYSE:BE), Plug Power (NASDAQ:PLUG), FuelCell Energy Inc (NASDAQ:FCEL), GrafTech International Ltd (NYSE:EAF).

Industry description

The industry produces a diverse range of electricity-powered equipment, appliances and components, catering to both households and industries. The products include power, distribution and specialty transformers; electric motors, generators and motor-generator sets; switchgear and switchboard apparatus; light bulbs, tubes, fittings and electric signs etc. Consumer income, construction spending, and industrial production are major drivers of demand for this industry’s products. Large companies tend to have economies of scale in production, marketing, and distribution, while smaller companies can potentially carve out their own market through niche or specialty offerings. The US electrical products manufacturing industry includes about 5,700 establishments (single-location companies and units of multi-location companies) with combined annual revenue of about $125 billion. (according to a study published in First Research). Emerson Electric Co., Hubbell Incorporated and Eaton Corporation plc are major electrical products makers in the U.S.

Market Cap

The average market capitalization across the Electrical Products Industry is 5.46B. The market cap for tickers in the group ranges from 750 to 205.24B. CYATY holds the highest valuation in this group at 205.24B. The lowest valued company is EDYYF at 750.

High and low price notable news

The average weekly price growth across all stocks in the Electrical Products Industry was 0%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -8%. NEOV experienced the highest price growth at 39%, while EPOW experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the Electrical Products Industry was 55%. For the same stocks of the Industry, the average monthly volume growth was 68% and the average quarterly volume growth was 50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 74
Price Growth Rating: 63
SMR Rating: 84
Profit Risk Rating: 84
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
BE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of on-site electric power solutions

Industry ElectricalProducts

Industry
Electrical Products
Address
4353 North First Street
Phone
+1 408 543-1500
Employees
2214
Web
https://www.bloomenergy.com
Interact to see
Advertisement
I've been following Viridian Therapeutics (VRDN) closely, and the stock has seen quite a bit of turbulence lately due to key updates in its thyroid eye disease (TED) portfolio. Shares dropped sharply after the Phase 3 topline data for the subcutaneous candidate elegrobart came out, even though it hit the primary endpoint. Investors reacted to efficacy and safety results that didn't quite match the high expectations. Trading volume spiked dramatically, which shows just how much attention the market is paying. From what I see, sentiment is still linked to the company's pipeline progress, including the FDA review of the intravenous asset veligrotug. Near-term pressures are there, but with solid cash reserves and several catalysts ahead, VRDN remains a compelling biotech play for those who can handle the volatility.
I've been following Planet Labs PBC (PL) closely, and one aspect that stands out is its operation of the world's largest constellation of earth-imaging satellites. This setup delivers daily global coverage, giving it a clear edge in geospatial intelligence. The "one-to-many" model allows for scalable economics, setting it apart from legacy providers that depend on exclusive image sales. The platform combines satellite data with AI-driven analytics, targeting sectors such as agriculture, defense, forestry, and insurance.
United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.
I've been following Rocket Pharmaceuticals (RCKT) closely as a late-stage biotech focused on gene therapies for rare pediatric diseases, using both lentiviral vector (LVV) and adeno-associated virus (AAV) platforms. What stands out to me is the company's strategic shift toward AAV-based cardiovascular programs—Danon disease, PKP2-ACM, and BAG3-DCM—which target areas with significant unmet needs and larger markets compared to traditional hematology indications. The recent FDA approval of KRESLADI marks Rocket's entry into commercialization, giving the team valuable launch experience and confirming the strength of its manufacturing setup.
I've been keeping an eye on KDK, and it's clear the company is well-positioned in the autonomous vehicle space, with a focus on AI-powered solutions for long-haul trucking, industrial applications, and defense. Founded in 2018 and based in Mountain View, California, Kodiak AI develops the Kodiak Driver—a modular, vehicle-agnostic virtual driver that integrates advanced AI software with hardware to enable driverless operations. This platform tackles key challenges like U.S. truck driver shortages and safety concerns, where human error accounts for over 85% of crashes.
SE stock declined -21% over the past 30 days, primarily triggered by a Q4 2025 earnings EPS miss despite revenue beat, leading to a sharp 16% single-day drop. Over the past quarter, the stock fell -37%, reflecting sustained pressure from analyst price target cuts and concerns over rising growth investments.
As I review the cybersecurity space, PANW stands out with its commanding position, holding a 28.4% share in network security as of 2024. This leadership stems from its evolution from point solutions to a unified platform that includes Strata for network security, Prisma for cloud and SASE, and Cortex for AI-powered security operations. The platformization strategy is key here—it encourages customers to consolidate their fragmented tools, which reduces complexity and costs while driving NGS ARR growth. In Q2 FY2026, NGS ARR rose 33% year-over-year to $6.3 billion.
TaskUs, Inc. (TASK) stands out as a leading provider of outsourced digital services and next-generation customer experience solutions. The company focuses on digital customer experience (Digital CX), trust and safety (monitoring user-generated content for compliance), and artificial intelligence (AI) services such as data labeling and annotation for machine learning models. From its headquarters in New Braunfels, Texas, TaskUs serves high-growth sectors like social media, e-commerce, gaming, streaming, food delivery, ride-sharing, technology, financial services, and healthcare.
WVE stock plunged approximately -52% over the past 30 days, driven primarily by disappointing high-dose data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 on March 26, which erased prior gains from positive initial results. Over the past quarter, shares declined around -61%, reflecting high volatility in biotech sentiment amid clinical trial outcomes and broader sector pressures on clinical-stage firms
KOD stock surged +39% over the past 30 days, driven primarily by positive Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy. Over the past quarter, shares gained +36%, reflecting anticipation of clinical catalysts and a successful $184 million capital raise.
Lam Research Corporation stands out as a leading supplier of semiconductor processing equipment essential for fabricating integrated circuits. The company designs, manufactures, markets, refurbishes, and services tools for deposition, etch, and clean processes, serving major chipmakers across the United States, China, Korea, Taiwan, Japan, and Europe. At its core, Lam's business revolves around innovative systems like ALTUS for film deposition and SABRE for electrochemical deposition, which are vital for advanced nodes in AI, memory, and logic chips.
Roblox Corporation (RBLX) runs a platform where millions of users create and dive into immersive 3D experiences. The business centers on a virtual economy: users buy Robux for in-game items, and creators cash out through the developer exchange (DevEx) program. In the online gaming space, Roblox stands out as a metaverse pioneer, going up against the likes of Epic Games' Fortnite and newer AI-driven platforms. The fundamentals reflect impressive user growth—daily active users (DAUs) reached 144 million in Q4 2025, a 69% jump year-over-year—but ongoing net losses underscore the heavy spending on infrastructure, AI, and safety. From what I see, this tension between growth and profitability has fueled much of the recent volatility in RBLX shares, as investors weigh strong engagement against shrinking margins.
Megan Holdings Limited (MGN) is a Malaysia-based company focused on the development, construction, maintenance, and upgrade of aquaculture and agriculture farms, along with related services. At its core, the business provides end-to-end solutions for shrimp farms, from design and building hatcheries to ongoing maintenance. It operates mainly in Sabah, Malaysia, across segments like aquaculture/agriculture, industrial solutions such as smart technologies, and investments in marketable securities.
Megan Holdings Limited (MGN), based in Kuala Lumpur and founded in 2020, focuses on developing, constructing, maintaining, and upgrading aquaculture and agriculture farms in Malaysia. The company operates in three segments—aquaculture and agriculture, industrial solutions like supplying smart technologies and machinery rentals, and investments in marketable securities—carving out a niche in engineering and construction within the Industrials sector. Its subsidiary status under Star Sprite Limited adds a layer of operational stability.
Pony AI Inc. (PONY) stands out as a leading player in autonomous mobility, dedicated to bringing self-driving technology to commercial use. Founded in 2016 and based in Guangzhou, China, the company operates across China, the U.S., and other international markets, offering robotaxi services, robotruck logistics, and licensing for intelligent driving solutions. Its business model leans heavily on asset-light partnerships with original equipment manufacturers (OEMs), transportation network companies (TNCs), and logistics platforms.
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases. In my view, the company's core strength lies in its proprietary Maze Compass platform, which uses human genetics and variant functionalization to identify and advance therapies targeting genetically defined patient populations.
In my view, JPM stands out as the largest U.S. bank by assets and market capitalization, commanding leading market shares across key segments. It holds approximately 11.1% of U.S. retail deposits, 23.6% of credit card sales volume, 8.4% of global investment banking fees, 11.8% of markets revenue, and 10% of treasury services revenue. This diversified "universal banking model" spans consumer and community banking, commercial and investment banking, and asset and wealth management, generating resilient revenue streams.
In recent sessions, WMT has held steady around $124, pulling back from February highs near $134. From what I see, this resilience stands out as the stock has outperformed broader indices year-to-date, thanks to its defensive role in groceries and essentials. Shoppers are leaning toward value options, and consistent volumes show ongoing institutional support. The premium valuation reflects confidence in Walmart's omnichannel progress and market share gains. Even with macro headwinds, I view WMT as a portfolio staple during uncertain times.
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.